Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

National Organization for Rare Disorders (NORD) Sponsors Rare Disease Summit
A shortage of new pharmaceutical products in the pipeline-combined with new scientific tools-has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said at a conference hosted by the National Organization for Rare Disorders (NORD).
generic viagra online
Phase 1 Study For Halozyme's Insulin-PH20 Published, Highlights Findings For Faster Acting Insulin Formulations
Halozyme Therapeutics, Inc. (Nasdaq: HALO), announced publication of a Phase 1 study reporting an acceleration of insulin absorption and increased insulin effects within minutes after co-administration of its hyaluronidase (PH20) enzyme with two mealtime insulin products, Humulin® R (regular human insulin) and Humalog® (insulin lispro). A rapid and short-acting insulin profile would more closely mimic the mealtime insulin release that occurs in non-diabetics and could lead to improved treatment for diabetes patients. These results were published in the June 2009 issue of the journal Diabetes Technology & Therapeutics.
News of the day
Advocates At Kenya Conference Explore New Strategies To Combat HIV/AIDS In Africa
Nearly 30 years after the emergence of HIV/AIDS, the global health community must develop new strategies to curb the spread of the disease in sub-Saharan Africa, some experts said Tuesday ahead of the Global Citizens Summit for Social Mobilization to End AIDS in Nairobi, Kenya, AFP/Google.com reports. The advocates also stressed the need for innovative approaches to health financing as international donors shift their attention toward other issues and as the ongoing economic downturn threatens fundraising prospects. The conference, which opens Wednesday, includes participants from 32 countries, primarily in Africa.According to Wasai Jacob Nanjakululu of Oxfam, about 90% of HIV-positive people are unaware of their status and 70% of people in need of treatment are not accessing medical care. Leonard Okello, an HIV/AIDS specialist with ActionAid International, added that the global health community is "far from winning the struggle against" HIV/AIDS. Okello said the conference will examine the shortcomings of earlier HIV/AIDS policies and explore new methods to address the disease. "There are a lot of res in HIV/AIDS programs but not much of that reaches the community," Okello said, asking, "What is it that we should radically change?" (AFP/Google.com, 5/26). According to IRIN/PlusNews, conference participants also plan to discuss "people-centered" approaches to combating HIV/AIDS at the Nairobi meeting. ActionAid Report Calls For Improvements in Basic Health Care To Address HIV/AIDS
Health Insurance

MS Society Calls On Brown To Ring-fence Stem Cell Funds

The MS Society has called on Gordon Brown to ring-fence funds for stem cell research into multiple sclerosis (MS). Four years ago the UK Government announced a ÷£50 million windfall for stem cell science but there has been no evidence of significant UK advances in research into conditions such as multiple sclerosis (MS). Without a commitment to target funding of UK stem cell trials, the charity has said research into the benefit of stem cells may be at risk of going down a blind alley. And without evidence of fruitful UK trials into the benefit of stem cells, patients will continue to seek unproven therapies abroad, it warned. The organisation, which supports more than 85,000 people with MS, is calling for a specific injection of ÷£3m for translational research into regenerative medicine - taking stem cells from the scientist"s bench to trials in patients. This is ahead of an International Stem Cell Consensus meeting on Wednesday (20 May) convened by the charity to bring world leaders in stem cell research together to gain a consensus view on how best to proceed with clinical testing of stem cells in order to speed up the development of a potential therapy for MS. UK experts will also brief MPs at a meeting of the All Party Parliamentary Group on MS on Tuesday (19 May), telling them that without action, British stem cell research is in danger of stalling, to the further detriment of patients in search of effective treatment. MS Society Chief Executive, Simon Gillespie, said: "Unless there"s tangible funding of properly regulated clinical trials people with MS will continue to see no option but to try potentially dangerous and unproven therapies abroad. "We want to work with government to make sure that underfunded neurological conditions like MS benefit from intelligent investment and that stem cell research in this country continues to thrive." Professor Robin Franklin, who is Director of the MS Society"s Cambridge Centre for Myelin Repair, which carries out early stage stem cell research, said stem cell research in the UK needed the full support of the Government. He added: "There is a concern among the medical research community that the lack of adequate levels of targeted funding is contributing toward the UK losing its place at the forefront of stem cell related research initiatives. "This, in turn, is having a detrimental impact on people with MS in this country, by sending out the message that their condition is not being given sufficiently high priority." Targeted funding for gene therapy, announced in 2003, has reaped rewards for a number of single gene disorders and seen significant research milestones into the congenital disease cystic fibrosis. Mr Gillespie added: "The government has not run shy of prioritising funds for cancer, mental health and heart disease and the MS Society believes it"s time it gave a boost to stem cell research into neglected long term conditions such as MS." MS Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009